"In den Kompetenznetzwerken arbeiten auf breiter Basis niedergelassene Fachärzte zusammen. Dadurch wird es möglich, einer Vielzahl potentieller Studienpatienten in kürzester Zeit neue Therapiemöglichkeiten anzubieten. Wenn Sie als Patient an einer Studie teilnehmen, werden alle die Studie betreffenden Behandlungen und Untersuchungen in einer speziellen Studienambulanz durch qualifizierte Prüfärzte durchgeführt. Ihre "normale" Weiterbehandlung erfolgt weiterhin bei Ihrem Arzt des Vertrauens. Die Intensivierung der Zusammenarbeit zwischen allen Partnern und der damit verbundene Informationsaustausch wird u.a. mittels moderner Kommunikationsformen erreicht."

During the past decade, POIS Leipzig GbR conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 3 clinical trials were completed, i.e. on average, 30% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "POIS Leipzig GbR" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Galecto Biotech AB" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "POIS Leipzig GbR" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Syneos Health" with 1 trials as a collaborator and "bioRASI, LLC" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "POIS Leipzig GbR" are "Carcinoma, Non-Small-Cell Lung" (2 trials), "Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification" (1 trials), "Allergic Rhinitis" (1 trials), "Allergic Rhinoconjunctivitis" (1 trials) and "Asthma" (1 trials). Many other conditions were trialed in "POIS Leipzig GbR" in a lesser frequency.

Most popular intervention types in "POIS Leipzig GbR" are "Drug" (12 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Docetaxel" (2 trials), "Osimertinib" (2 trials), "Tepotinib" (2 trials) and "AMG 510" (1 trials). Other intervention names were less common.

The vast majority of trials in "POIS Leipzig GbR" are 14 trials for "All" genders.

Currently, there are NaN active trials in "POIS Leipzig GbR". undefined are not yet recruiting, undefined are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in POIS Leipzig GbR, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in POIS Leipzig GbR, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".